LANGERHANS CELL HISTIOCYTOSIS: Retrospective Analysis of 217 Cases in a Single Center

Langerhans cell histiocytosis (LCH) is a disorder with unclear etiology and pathogenesis, which is characterized by abnormal clonal proliferation and accumulation of langerhans cells at various tissue and organs. A total of 217 patients with LCH were evaluated retrospectively for clinicopathological...

Full description

Saved in:
Bibliographic Details
Published in:Pediatric hematology and oncology 2008-01, Vol.25 (5), p.399-408
Main Authors: Ya c, Begül, Varan, Ali, Ça lar, Melda, Söylemezo lu, Figen, Sungur, Arzu, Orhan, Diclehan, Yalç n, Bilgehan, Akyüz, Canan, Kutluk, Tezer, Büyükpamukçu, Münevver
Format: Article
Language:English
Subjects:
Adolescent
Child
Child, Preschool
children
Female
Histiocytosis, Langerhans-Cell - mortality
Histiocytosis, Langerhans-Cell - pathology
Histiocytosis, Langerhans-Cell - therapy
Humans
Infant
Langerhans cell histiocytosis
Male
outcome
Prognosis
prognostic factors
Retrospective Studies
Survival Analysis
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Langerhans cell histiocytosis (LCH) is a disorder with unclear etiology and pathogenesis, which is characterized by abnormal clonal proliferation and accumulation of langerhans cells at various tissue and organs. A total of 217 patients with LCH were evaluated retrospectively for clinicopathological features, laboratory findings, treatment modalities, long-term outcome, and factors affecting the outcome. Median age at the time of diagnosis was 3.5 years and male/female ratio was 1.8. The most common complaint at presentation was a bone lesion-related symptom. Fifty percent of the patients younger than 2 years had organ dysfunction (OD). Treatment consisted of surgery, chemotherapy, and radiotherapy alone or in combination. Vinblastine with or without prednisolone was the most common used chemotherapy regimen. Overall (OS) and event-free survival (EFS) rates were 84% and 51.5%, respectively, at an 8-year median follow-up time. Overall survival was significantly lower in patients younger than 2 years of age and patients with OD. The age at diagnosis, pulmonary, liver, or hematological involvement, and elevated acute-phase reactants were found to have a statistically significant effect on the OS or EFS rates.
ISSN:0888-0018
1521-0669
DOI:10.1080/08880010802107356